OIOmer Faruk Ipek

Omer Faruk Ipek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Omer Faruk Ipek has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Flexible bronchoscopy in pediatric atelectasis: bronchoscopic findings, management changes, and factors associated with radiographic resolution

    by Ömer Faruk İpEk, Ebru Yalçın, Özge Özen, Birce Sunman, Nagehan Emiralioğlu Ordukaya, Deniz Doğru, Uğur Özçelik, Nural Kiper

    Background. Flexible bronchoscopy (FB) is widely used in children with atelectasis; however, the optimal timing of FB and the influence of underlying disease on radiographic resolution remain uncertain. We aimed to describe bronchoscopic and microbiological findings, subsequent management changes, radiographic outcomes, and factors associated with atelectasis resolution in children who underwent FB. Methods. This retrospective cohort included 108 children (0–18 years) who underwent FB for atelectasis between 2017 and 2022 with chest radiograph-based follow-up. Outcomes were immediate radiographic response and final radiographic status. An exploratory Cox model assessed time to complete resolution and included detection-to-FB interval, macroscopic pathological findings, congenital heart disease, primary ciliary dyskinesia, immunodeficiency, asthma and cystic fibrosis. Results. Median age at FB was 4.9 years (IQR: 2.5–8.8; range: 14 days to 18 years). 67/108 patients (62.0%) had underlying disorders. Macroscopic pathological findings were observed in 95.4%. Bronchoalveolar lavage cultures were positive in 75/105 patients (71.4%) and additional treatment was administered in 67/108 patients (62.0%). At final radiographic status, complete, partial, and no resolution were observed in 44/108 (40.7%), 30/108 (27.8%), and 34/108 patients (31.5%), respectively. In the exploratory Cox model, each 30-day increase in detection-to-FB interval was associated with a lower hazard of complete resolution (HR: 0.88, 95% CI: 0.80–0.98; p=0.018), but this association was attenuated after excluding intervals >365 days (p=0.169). Procedure-related complications occurred in 4/108 patients (3.7%). Conclusions. In selected children undergoing FB for atelectasis, bronchoscopy frequently revealed clinically relevant bronchoscopic and microbiological findings, informed subsequent management, and was followed by partial or complete radiographic resolution in more than two-thirds of patients. Although the timing-related findings should be interpreted cautiously, particularly because the association was attenuated in sensitivity analysis, this study supports the role of FB as a complementary diagnostic and management-guiding tool in pediatric atelectasis.

  • Longitudinal Impact of Pseudomonas aeruginosa Versus Haemophilus influenzae Colonization on Lung Function Decline in Children With Primary Ciliary Dyskinesia

    by Ömer Faruk İpEk, Nagehan Emiralioğlu Ordukaya, Aslı Kuzu Kuşaklı, Meltem Akgül Erdal, Havva İpEk Demir, Ebru Yalçın, Deniz Doğru, Uğur Özçelik

    Background: The association of Pseudomonas aeruginosa (PsA) and Haemophilus influenzae (HI) colonization with lung function in children with primary ciliary dyskinesia (PCD) remains insufficiently defined. We aimed to compare spirometric parameters between PsA‐ and HI‐colonized children and evaluate longitudinal changes before, at, and after chronic colonization. Methods: This retrospective cohort included patients aged ≥ 5 years with definite or highly probable PCD and chronic PsA or HI colonization. Chronic colonization was defined using repeated sputum cultures over 12 months. Pulmonary function tests were analyzed 1 year before colonization, at colonization, and 1 year after colonization. FEV1, FVC, and FEF25–75 were reported as percent‐predicted values and GLI 2012 z‐scores. Individual pre‐to‐after‐colonization change scores and bronchiectasis subgroup analyses were performed. Results: Among 290 patients with PCD, 40 met inclusion criteria: 10 with PsA and 30 with HI colonization. PsA‐colonized patients were older at colonization than HI‐colonized patients (17 [12–23] vs. 11 [9–15] years, p = 0.011), and bronchiectasis was more frequent in the PsA group (100% vs. 60%, p = 0.019). PsA colonization was associated with lower lung function across several spirometric measures. Both groups showed significant within‐group declines in FEV1 and FEF25–75 over time. However, individual pre‐to‐after‐colonization changes in FEV1 and FEF25–75 z‐scores did not differ significantly between groups, including in the bronchiectasis subgroup analysis. Conclusions: PsA colonization was associated with lower lung function than HI colonization, but not with significantly greater longitudinal decline. These findings suggest that PsA may mark more advanced disease rather than independently accelerating functional loss. Larger prospective studies with non‐colonized comparators are needed.

  • Open Access

    Adverse Events Associated with CFTR Modulator Therapy: Experience from a Tertiary Care Center

    by Dilara Demirel, Ebru Güneş Yalçın, Hanife Avcı, Uğur Özçelik, Umay Kavgacı, Tuğçe Kantemir, Ömer Faruk İpEk, Nagehan Emiralioğlu Ordukaya, Deniz Doğru

    Objective: This study aimed to evaluate the frequency, nature, and potential factors associated with adverse events associated with cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy in a pediatric cystic fibrosis (CF) population. Methods: A single-center, retrospective cohort study was conducted at a tertiary care center. Pediatric patients with CF who received CFTR modulator therapy (ivacaftor monotherapy or elexacaftor/tezacaftor/ivacaftor combination) between January 2021 and January 2025 were included. Clinical characteristics and adverse events were analyzed, and patients with and without adverse events were compared. Results: The study included 100 patients (mean age, 141.5 ± 55.3 months). Adverse events were reported in 24 (24%) patients. Patients experiencing adverse events were significantly older than those who did not (P=.026). The most frequent adverse events were skin rash (33.3%), elevated creatine kinase (20.8%), and gastrointestinal complaints (12.5%). Treatment interruption was required in 12 patients; however, only 1 patient permanently discontinued therapy due to persistent rash and elevated liver enzymes. No severe hepatic or systemic complications occurred. Conclusion: Cystic fibrosis transmembrane conductance regulator modulators are generally well tolerated in the pediatric population. Most adverse events are mild, transient, and manageable through routine monitoring and temporary cessation, allowing for the safe continuation of therapy.

  • Exploring Social Determinants of Health in Primary Ciliary Dyskinesia

    by Meltem Akgül Erdal, Tuğçe Kantemir, Ömer Faruk İpEk, Deniz DoğrU, Ebru Yalçın, Nagehan Emiralioğlu, UğuR ÖzÇeLik

    Background: Primary ciliary dyskinesia (PCD) is a genetic ciliopathy characterized by a diverse clinical presentation with marked respiratory complications and adversely impacts quality of life. However, the lived experience of individuals with PCD extends beyond biological complications, intersecting with social determinants of health (SDoH). The role of SDoH in the context of PCD remains insufficiently characterized. Objective: This cross‐sectional study aimed to assess the current picture of SDoH insecurity among primary caregivers of pediatric PCD/highly likely PCD patients. Methods: The study was conducted at a tertiary care center in Türkiye, from March 1 to October 31, 2024. Primary caregivers of children aged 6–18 years with PCD/highly likely PCD were surveyed using the “Your Current Life Situation” questionnaire. Data on caregiver demographics, income, education, smoking status, and household conditions were collected. Clinical data (BMI, FEV1, hospitalizations, and annual antibiotic courses) were retrieved from patient records. Descriptive statistics and nonparametric tests were applied using SPSS 22.0. Results: Among 67 respondents (response rate: 73%), 89.6% reported insecurity in ≥ 1 of six SDoH domains. The most common issues were social support/stress (73.1%), healthcare access (53.7%), and financial hardship (49.3%). Most families (86.5%) lived below the poverty line; 55.2% of caregivers had inadequate health literacy. Conclusions: A high prevalence of SDoH insecurity was identified among caregivers of children with PCD/highly likely PCD, highlighting unmet psychosocial and healthcare access needs. The substantial proportion of caregivers requiring support underscores the the need for routine SDoH screening, caregiver support, and targeted interventions to promote health equity in PCD patients.

  • The Evaluation of the Genotype and Phenotype Relationship in Patients With Nasal Polyps in Cystic Fibrosis Registry of Turkey

    by Handan Kekeç, Tuğba Şişmanlar Eyüboğlu, Ayşe Tana Aslan, Volkan Medeni, Ebru Yalçın, Ömer Faruk İpEk, Tugçe Kantemir, Bahar Ece Tokdemir, Fatma Nur Ayman, Figen Gülen, et al.

    Introduction: Cystic fibrosis (CF) is a complex genetic disorder characterized by significant clinical heterogeneity. We aimed to investigate the genotype‐phenotype relationship of nasal polyps (NP) in CF Registry of Turkey (CFRT). Methods: The study included all children registered in the CFRT in 2023, divided into two groups based on NP presentation. Clinical and demographic data were compared. The Sinus‐Nasal Quality of Life (QoL) Survey‐5(SN‐5) evaluated patients with NP history. Results: A total of 2258 patients were registered, with 115 (5.1%) having NP and 2143 without NP. Age was higher in the NP group ( p < 0.001). The first and second sweat tests were higher in the NP group ( p < 0.05). Median FEV1% was 89 (31–133) for the NP group and 85 (15–142) for those without NP ( p = 0.015). Chronic colonization of MSSA and MRSA, CF‐related liver disease, and CF‐related diabetes were also more common in NP ( p < 0.05). No differences were detected in pulmonary exacerbations ( p > 0.05). In the NP group, severe genotype and F508del were more frequent ( p < 0.05). Elexacaftor/tezacaftor/ivacaftor use was more common in NP ( p = 0.003). A weak negative correlation was found between age and the SN‐5 score ( p = 0.020, r = −0.231), as well as a weak positive correlation between age and the Visual Analog Scale (VAS) ( p = 0.001, r  = 0.322). Conclusion: Although uncommon, NP is associated with more severe clinical and genetic characteristics in CF. These findings underscore the importance of integrating upper airway evaluation into CF management and highlight the potential for age‐related adaptation or improved symptom perception in older patients.

  • Open Access

    Original Article The Value of Flexible Bronchoscopy in the Diagnosis and Treatment of Atelectasis; A Single-Center Experience of 108 Pediatric Patients

    by Omer Faruk Ipek, Ebru Yalcin (Guest Editor), Özge Özen, Birce Sunman, Ismail Guzelkas, Halime Nayir Buyuksahin, Nagehan Emiralioğlu, Deniz Dogru, Ugur Ozcelik, Nural Kiper

    Introduction: The current literature lacks a comprehensive investigation into the use of flexible bronchoscopy (FB) in the treatment of childhood atelectasis. Methods: In this retrospective study, the data of pediatric patients who were diagnosed with atelectasis and underwent FB for diagnostic and therapeutic purposes in our center from January 1, 2017 to December 31, 2022 were retracted from medical records. The study aimed to assess the effectiveness of FB in diagnosing and treating atelectasis in children, identifying the appropriate patient population and the optimal timing for intervention. Results: A total of 108 children, with a median age of 4.9 years (14 days-18 years), underwent FB. At the time atelectasis was detected, at least one underlying disease was present in 62% of the patients. Based on the macroscopic and microscopic FB findings, 86.1% of the patients received a new diagnosis, and 83.3% of the patients were prescribed additional new treatments. At the last outpatient visit, complete resolution of the atelectasis was observed in 40.8% of patients, while 31.4% showed no resolution. The duration from the diagnosis of atelectasis to FB was shorter in patients with partial or complete resolution. Patients without additional radiological abnormalities or scoliosis had higher resolution rates, while those with congenital cardiac diseases, immunodeficiency, or primary ciliary dyskinesia had lower rates. Conclusion: Children with atelectasis who do not respond to conventional treatments within three weeks may undergo FB. Delayed FB contributes to failure in resolving atelectasis, prolonged recovery times, and increased recurrence rates, particularly in patients with underlying diseases.